Literature DB >> 12574425

Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Carlos Cepeda1, Raymond S Hurst, Christopher R Calvert, Elizabeth Hernández-Echeagaray, Oanh K Nguyen, Emily Jocoy, Lindsey J Christian, Marjorie A Ariano, Michael S Levine.   

Abstract

Alterations in the corticostriatal pathway may precede symptomatology and striatal cell death in Huntington's disease (HD) patients. Here we examined spontaneous EPSCs in striatal medium-sized spiny neurons in slices from a mouse model of HD (R6/2). Spontaneous EPSC frequency was similar in young (3-4 weeks) transgenics and controls but decreased significantly in transgenics when overt behavioral symptoms began (5-7 weeks) and was most pronounced in severely impaired transgenics (11-15 weeks). These differences were maintained after bicuculline or tetrodotoxin, indicating they were specific to glutamatergic input and likely presynaptic in origin. Decreases in presynaptic and postsynaptic protein markers, synaptophysin and postsynaptic density-95, occurred in 11-15 week R6/2 mice, supporting the electrophysiological results. Furthermore, isolated, large-amplitude synaptic events (>100 pA) occurred more frequently in transgenic animals, particularly at 5-7 weeks, suggesting additional dysregulation of cortical inputs. Large events were blocked by tetrodotoxin, indicating a possible cortical origin. Addition of bicuculline and 4-aminopyridine facilitated the occurrence of large events. Riluzole, a compound that decreases glutamate release, reduced these events. Together, these observations indicate that both progressive and transient alterations occur along the corticostriatal pathway in experimental HD. These alterations are likely to contribute to the selective vulnerability of striatal medium-sized spiny neurons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574425      PMCID: PMC6741903     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

1.  Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity.

Authors:  A J Morton; W Leavens
Journal:  Brain Res Bull       Date:  2000-05-01       Impact factor: 4.077

2.  Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

Authors:  R J Carter; L A Lione; T Humby; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

3.  Is pharmacological neuroprotection dependent on reduced glutamate release?

Authors:  P Calabresi; B Picconi; E Saulle; D Centonze; A H Hainsworth; G Bernardi
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

4.  Riluzole therapy in Huntington's disease (HD).

Authors:  H D Rosas; W J Koroshetz; B G Jenkins; Y I Chen; D L Hayden; M F Beal; M E Cudkowicz
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

5.  Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation.

Authors:  L A Lione; R J Carter; M J Hunt; G P Bates; A J Morton; S B Dunnett
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

6.  Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease.

Authors:  M S Levine; G J Klapstein; A Koppel; E Gruen; C Cepeda; M E Vargas; E S Jokel; E M Carpenter; H Zanjani; R S Hurst; A Efstratiadis; S Zeitlin; M F Chesselet
Journal:  J Neurosci Res       Date:  1999-11-15       Impact factor: 4.164

7.  Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.

Authors:  B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

8.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.

Authors:  O Hansson; A Petersén; M Leist; P Nicotera; R F Castilho; P Brundin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.

Authors:  K P Murphy; R J Carter; L A Lione; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

10.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease.

Authors:  E Sapp; J Penney; A Young; N Aronin; J P Vonsattel; M DiFiglia
Journal:  J Neuropathol Exp Neurol       Date:  1999-02       Impact factor: 3.685

View more
  124 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 3.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

Authors:  Birgit Zucker; Jibrin A Kama; Alexandre Kuhn; Doris Thu; Lianna R Orlando; Anthone W Dunah; Ozgun Gokce; David M Taylor; Johann Lambeck; Bernd Friedrich; Katrin S Lindenberg; Richard L M Faull; Cornelius Weiller; Anne B Young; Ruth Luthi-Carter
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

5.  Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum.

Authors:  Roy M Smeal; Kristen A Keefe; Karen S Wilcox
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

6.  Genetic load determines atrophy in hand cortico-striatal pathways in presymptomatic Huntington's disease.

Authors:  Yi Hong; Lauren J O'Donnell; Peter Savadjiev; Fan Zhang; Demian Wassermann; Ofer Pasternak; Hans Johnson; Jane Paulsen; Jean-Paul Vonsattel; Nikos Makris; Carl F Westin; Yogesh Rathi
Journal:  Hum Brain Mapp       Date:  2018-05-24       Impact factor: 5.038

7.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012

8.  Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease.

Authors:  J Spampanato; X Gu; X W Yang; I Mody
Journal:  Neuroscience       Date:  2008-09-18       Impact factor: 3.590

9.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

10.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.